首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1477257

胃動力障礙藥物市場，依疾病類型，依藥物類別，依配銷通路，依地理位置

Gastric Motility Disorder Drug Market, By Disorder Type, By Drug Class, By Distribution Channel, By Geography

出版日期: 2024年04月03日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年胃動力障礙藥物市場價值為576.5億美元，預計到2031年將達到831.5億美元，2024年至2031年的年複合成長率（CAGR）為5.4%。

報告範圍		報告詳情
基準年：	2023年	2024 年市場規模：	576.5 億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測 2024 年至 2031 年複合年成長率：	5.40%	2031 年價值預測：	831.5 億美元

圖 1. 2024 年胃動力障礙藥物市場佔有率 (%)（依地區）

胃動力障礙是指胃需要比平常更多或更少的時間來排空其內容物的疾病。一些常見的胃動力障礙包括胃輕癱和功能性消化不良。當胃中的肌肉運動緩慢或紊亂，導致食物在胃中滯留的時間比正常情況更長時，就會發生胃輕癱。它會影響正常的消化過程，並經常引起噁心、腹脹和嘔吐。同樣，功能性消化不良涉及胃排空過程受損，導致上腹部不適。在許多情況下，胃動力障礙的確切原因尚不清楚；然而，它們可能是由於迷走神經損傷、糖尿病、某些藥物、手術或其他潛在的健康狀況而引起的。目前用於胃動力障礙的藥物療法包括旨在刺激胃動力並加速胃排空的促動力劑。鑑於此類疾病的慢性性質且缺乏徹底治癒方法，全球胃動力藥物市場預計將在未來幾年穩定成長。

市場動態：

全球胃動力藥物市場受到糖尿病盛行率不斷上升的推動，因為糖尿病是胃輕癱的高風險因素。與胃動力障礙相關的住院時間延長和工作效率下降也導致了他們日益沉重的經濟負擔。預計這將刺激對更有效藥物療法的需求。然而，由於缺乏針對某些類型胃動力障礙的核准藥物，市場潛力受到限制。此外，與現有藥物選擇相關的副作用構成了重大課題。開發具有更好安全性的新型藥物配方可以在這個市場上帶來利潤豐厚的機會。採用聯合療法和開發針對未滿足需求的特定區域配方是一些關鍵機會。

研究的主要特點：

該報告對全球胃動力障礙藥物市場進行了深入分析，並提供了預測期（2024-2031）的市場規模（十億美元）和年複合成長率（CAGR%），以2023年為基準年。
它闡明了不同區隔市場的潛在收入成長機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數描述了全球胃動力障礙藥物市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球胃動力障礙藥物市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球胃動力障礙藥物市場的各種策略矩陣輕鬆做出決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地區
歐洲
英國
德國
義大利
法國
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
東協
澳洲
韓國
亞太地區其他地區
中東
海灣合作理事會
以色列
中東其他地區
非洲
北非
中非
南非

第 9 章：競爭格局

公司簡介
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals

第 10 章：分析師觀點

命運之輪
分析師觀點
連貫的機會圖

第 11 章：參考文獻與研究方法

參考
研究方法論

簡介目錄

Product Code: CMI6849

The gastric motility disorder drug market is estimated to be valued at USD 57.65 Bn in 2024 and is expected to reach USD 83.15 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 57.65 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	5.40%	2031 Value Projection:	US$ 83.15 Bn

Figure 1. Gastric Motility Disorder Drug Market Share (%), By Region, 2024

Gastric Motility Disorder Drug Market - IMG1

Gastric motility disorder refers to conditions wherein the stomach takes more or less time than usual to empty its contents. Some common gastric motility disorders include gastroparesis and functional dyspepsia. Gastroparesis occurs when the muscle movements in the stomach are either sluggish or disordered, causing food to get stuck in the stomach for a longer duration than normal. It affects the normal digestive process and often causes nausea, bloating, and vomiting. Similarly, functional dyspepsia involves impaired gastric emptying processes leading to discomfort in the upper abdomen. The exact causes of gastric motility disorders are unknown in many cases; however, they may arise due to damage to the vagus nerve, diabetes, certain medications, surgery, or other underlying health conditions. Currently available drug therapies for gastric motility disorders include prokinetics that aim to stimulate gastric motility and hasten gastric emptying. Given the chronic nature and lack of complete cure for such disorders, the global gastric motility drug market is poised to grow steadily in the coming years.

Market Dynamics:

The global gastric motility drug market is driven by the increasing prevalence of diabetes as it is a high-risk factor for gastroparesis. Extended hospital stays and loss of work productivity associated with gastric motility disorders also contribute to their growing economic burden. This is anticipated to fuel the demand for more effective drug therapies. However, the market potential is restricted by the lack of approved drugs for some types of gastric motility disorders. Moreover, side effects associated with existing drug options pose a major challenge. Development of novel drug formulations with better safety profiles can present lucrative opportunities in this market. Adoption of combination therapies and development of region-specific formulations tailored to address the unmet needs are some key opportunities.

Key Features of the Study:

This report provides an in-depth analysis of the global gastric motility disorder drug market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global gastric motility disorder drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global gastric motility disorder drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastric motility disorder drug market.

Detailed Segmentation-

Disorder Type:
- Upper Digestive Tract
- Achalasia
- Gastroesophageal Reflux Disease (GERD)
- Gastroparesis
- Dumping Syndrome
- Lower Digestive Tract
- Intestinal Pseudo-obstruction
- Small Intestinal Bacterial Overgrowth (SIBO)
- Pelvic Dyssynergia
- Hirschsprung's Disease
Drug Class:
- Antacids
- Antidiarrheals
- Calcium-channel Blockers
- H2 Blockers
- Proton Pump Inhibitors
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disorder Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Gastric Motility Disorder Drug Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 impact on the market

5. Global Gastric Motility Disorder Drug Market, By Disorder Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Upper Digestive Tract
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Achalasia
Gastroesophageal Reflux Disease (GERD)
Gastroparesis
Dumping Syndrome
Lower Digestive Tract
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Intestinal Pseudo-obstruction
Small Intestinal Bacterial Overgrowth (SIBO)
Pelvic Dyssynergia
Hirschsprung's Disease

6. Global Gastric Motility Disorder Drug Market, By Drug Class, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Antacids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Antidiarrheals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Calcium-channel Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
H2 Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Proton Pump Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Gastric Motility Disorder Drug Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Gastric Motility Disorder Drug Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals